company background image
TE1 logo

Bio-Techne DB:TE1 Stock Report

Last Price

€64.00

Market Cap

€10.1b

7D

-3.8%

1Y

-3.0%

Updated

28 Mar, 2024

Data

Company Financials +

TE1 Stock Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

TE1 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Bio-Techne Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bio-Techne
Historical stock prices
Current Share PriceUS$64.00
52 Week HighUS$80.50
52 Week LowUS$49.40
Beta1.22
1 Month Change-5.19%
3 Month Change-9.22%
1 Year Change-3.03%
3 Year Change-22.42%
5 Year Change45.30%
Change since IPO459.20%

Recent News & Updates

Recent updates

Shareholder Returns

TE1DE Life SciencesDE Market
7D-3.8%0.5%1.8%
1Y-3.0%-5.1%5.7%

Return vs Industry: TE1 exceeded the German Life Sciences industry which returned -4.6% over the past year.

Return vs Market: TE1 underperformed the German Market which returned 7% over the past year.

Price Volatility

Is TE1's price volatile compared to industry and market?
TE1 volatility
TE1 Average Weekly Movement4.3%
Life Sciences Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market9.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: TE1 has not had significant price volatility in the past 3 months.

Volatility Over Time: TE1's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19763,050Kim Keldermanhttps://www.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Bio-Techne Corporation Fundamentals Summary

How do Bio-Techne's earnings and revenue compare to its market cap?
TE1 fundamental statistics
Market cap€10.12b
Earnings (TTM)€207.75m
Revenue (TTM)€1.06b

49.4x

P/E Ratio

9.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TE1 income statement (TTM)
RevenueUS$1.14b
Cost of RevenueUS$374.82m
Gross ProfitUS$770.18m
Other ExpensesUS$546.06m
EarningsUS$224.11m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.43
Gross Margin67.26%
Net Profit Margin19.57%
Debt/Equity Ratio22.8%

How did TE1 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

23%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.